Article

Rentschler Biopharma has appointed Dr. Veit Bergendahl as Chief Operating Officer and executive board member, effective April 1, 2026. Dr.

Bergendahl brings over 20 years of international leadership experience in biopharmaceutical development and manufacturing. He will oversee process development, cGMP manufacturing, engineering, technology, and production automation, contributing to the company's strategic direction and sustainable growth.